This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Holland, O. B. Articles by Anderson, R. J. Search for Related Content PubMed PubMed Citation Articles by Holland, O. B. Articles by Anderson, R. J.

Hypertension, Vol 5, 235-239, Copyright © 1983 by American Heart Association

ARTICLES

Synergistic effect of captopril with hydrochlorothiazide for the treatment of low-renin hypertensive black patients

OB Holland, L von Kuhnert, WB Campbell and RJ Anderson

Diuretics have been particularly successful for treatment of low-renin hypertension (LRH), although they may cause metabolic complications such as hypokalemia and hyperglycemia. Since the efficacy of diuretics is largely limited by reactive angiotensin II production, a combination of a converting enzyme inhibitor with a diuretic should be synergistic, particularly in LRH, where heightened aldosterone production in response to angiotensin II has been noted. Eighteen patients with LRH were treated initially with either captopril alone (450 mg/day) or hydrochlorothiazide (HCTZ) (up to 100 mg/day). Captopril alone only reduced average placebo standing blood pressure from 151/100 to 146/96 mm Hg. Combination of HCTZ with captopril reduced average standing blood pressure to 111/76 mm Hg at 3 months and 116/81 mm Hg at 1 year while allowing reductions in average captopril dosage to 100 mg/day and HCTZ dosage to 40 mg/day and reductions in supplemental potassium administration and in HCTZ-induced hyperglycemia. Captopril monotherapy did not increase urinary excretion of kallikrein, prostaglandin E2, or 6-keto prostaglandin F1 alpha, a metabolite of prostacyclin, and did not reduce urinary aldosterone excretion chronically. Thus, a synergism of captopril with HCTZ may be advantageous in certain patients with LRH.

This article has been cited by other articles:

				S. G. Chrysant Fixed Low-Dose Drug Combination for the Treatment of Hypertension Arch Fam Med, July 1, 1998; 7(4): 370 - 376. [Abstract] [Full Text] [PDF]

				S. G. Chrysant and The Lisinopril-Hydrochlorothiazide Group Antihypertensive Effectiveness of Low-Dose Lisinopril-Hydrochlorothiazide Combination: A Large Multicenter Study Arch Intern Med, April 11, 1994; 154(7): 737 - 743. [Abstract] [PDF]

				B. J. Materson and R. A. Preston Angiotensin-Converting Enzyme Inhibitors in Hypertension: A Dozen Years of Experience Arch Intern Med, March 14, 1994; 154(5): 513 - 523. [Abstract] [PDF]

				R. R. Townsend and O. B. Holland Combination of Converting Enzyme Inhibitor With Diuretic for the Treatment of Hypertension Arch Intern Med, June 1, 1990; 150(6): 1175 - 1183. [Abstract] [PDF]

				M. J. Prince, C. A. Stuart, M. Padia, Z. Bandi, and O. B. Holland Metabolic Effects of Hydrochlorothiazide and Enalapril During Treatment of the Hypertensive Diabetic Patient: Enalapril for Hypertensive Diabetics Arch Intern Med, November 1, 1988; 148(11): 2363 - 2368. [Abstract] [PDF]

				Veterans Administration Cooperative Study Group on Low-Dose Captopril for the Treatment of Mild to Moderate Hypertension: I. Results of a 14-Week Trial Arch Intern Med, October 1, 1984; 144(10): 1947 - 1953. [Abstract] [PDF]